MedTrace Logo

SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access

NCT02214134 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 539

Last updated 2025-08-17

No results posted yet for this study

Summary

SPECTAlung is a program aiming at screening patients with thoracic tumors to identify the molecular characteristics of their disease. The thoracic tumors include lung cancer, malignant pleural mesothelioma, thymoma or thymic carcinoma at any stage. Once the molecular characteristics are identified, there might be the possibility to offer these patients access to targeted clinical trials.

Conditions

  • Any Stage of Lung Cancer (Any Histotype)
  • Any Stage of Malignant Pleural Mesothelioma
  • Any Stage of Any Thymic Malignancy

Interventions

GENETIC

Tumour markers testing

Sponsors & Collaborators

  • ETOP IBCSG Partners Foundation

    collaborator NETWORK

  • European Organisation for Research and Treatment of Cancer - EORTC

    lead NETWORK

Principal Investigators

  • Benjamin Besse, MD, PhD · Gustave Roussy, Cancer Campus, Grand Paris

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-22
Primary Completion
2020-10-22
Completion
2021-05-12

Countries

  • Belgium
  • France
  • Ireland
  • Italy
  • Poland
  • Slovenia
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02214134 on ClinicalTrials.gov